Webinar: Power of data & specimen archive for discovery & development View now!

Delivering a complete lung cancer solution for you and your patients

Trust the experts with over 20 years of experience. 

hero anchor
Tests & services

Lung cancer impacts 1 in 17 men and 1 in 18 women.1

NeoGenomics offers a comprehensive lung cancer solution that supports the care continuum with tests that detect genomic alterations for diagnosis, therapy selection, prognosis, and clinical trial options. We meet you and your patients where they are. Whether their disease is newly diagnosed or recurrent, our lung cancer solution aims to provide the information you need to treat with confidence. While the treatment landscape for advanced-stage non-small cell lung cancer (aNSCLC) has grown increasingly complex, NeoGenomics aims to simplify biomarker testing by offering both tissue and liquid biopsy comprehensive genomic profiling (CGP) options that take the guesswork out of the process.

Featured lung cancer solutions

Comprehensive testing for aNSCLC patients

In the era of precision medicine, the number of FDA-approved targeted therapy options has accelerated; this is particularly true for lung cancer. Up to 70% of advanced-stage NSCLC patients have a known oncogenic driver mutation, many of which are associated with an approved therapy.2 Comprehensive profiling with next-generation sequencing identifies targetable genomic alterations and ensures the best therapy is provided to the patient, improving patient outcomes. 

The PanTracer portfolio provides CGP testing from either tissue or liquid biopsy samples. The broad panels cover key biomarkers recommended by clinical practice guidelines. ​

PanTracer Tissue and PanTracer LBx can be ordered individually or together to maximize genomic insights.

Guideline-driven biomarker detection for lung cancer​3-6

chart

MSI, microsatellite instability; TMB, tumor mutation burden.

Add-on testing for therapy selection

Older man hiking and smiling

Concurrent testing

PanTracer Tissue and PanTracer LBx can be ordered either simultaneously or as an automated reflex when tissue testing fails.

Simultaneous tissue — and liquid-based testing is a practical and time-saving method for identifying actionable biomarkers for therapy decisions, ensuring fully informed choices for the best possible patient outcomes by expediting the time to treatment and reducing delays due to insufficient tissue.

My liquid biopsy test has potentially bought me several more years that I wouldn’t have had otherwise. That’s something that money can’t buy.
— Sasha, patient

References

  1. American Cancer Society. Key Statistics for Lung Cancer. American Cancer Society. Updated January 16, 2025. Accessed August 14, 2025. https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html 

  2. Hirsch FR, Suda K, Wiens J, Bunn PA, Jr. New and emerging targeted treatments in advanced non-small-cell-lung-cancer. Lancet. Sep 3 2016.388(10048): 1012-1024. 

  3. Moore DC, et al. The role of biomarkers in guiding clinical decision-making in oncology. J Adv Pract Oncol. 2023;14(3):241-248.

  4. SSpacegen. New markers of lung cancer seen from the 2025 NSCLC NCCN guideline V1. Published December 30, 2025. Accessed March 25,2025. https://sspacegen.com/en/newsinfo.aspx?newsID=417&CateId=109&parentid=0

  5. Yang M, et al. Non-small cell lung cancer with MET amplification: review of epidemiology, associated disease characteristics, testingprocedures, burden, and treatments. Front Oncol. 2024;13:1241402.

  6. U.S. Food and Drug Administration. FDA grants accelerated approval to telisotuzumab vedotin (TeliV) for NSCLC with high c-Met protein overexpression. Published July 2, 2025. Accessed July 10, 2025.
    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approvaltelisotuzumab-
    vedotin-tllv-nsclc-high-c-met-protein-overexpression

Still have questions?

We pride ourselves on our unparalleled Client Services team. If you have questions regarding test information, specimen requirements, turnaround times, test add-ons, or patient results, please email us at client.services@neogenomics.com or call 866.776.5907, Option 3.